Laurus Labs Limited has been recognized for its sustainability leadership and featured in the prestigious S&P Global Sustainability Yearbook 2026. The pharmaceutical company's inclusion in this global ranking demonstrates its strong commitment to environmental, social, and governance (ESG) practices relative to industry peers worldwide.

Significant Improvement in Sustainability Score

The company achieved a notable improvement in its sustainability performance metrics. Laurus Labs secured an S&P Global Corporate Sustainability Assessment (CSA) score of 81 out of 100 in the pharmaceutical companies category, representing a substantial increase from the previous year's score of 71 out of 100.

Exclusive Global Recognition

The S&P Global Sustainability Yearbook distinguishes companies within their industries that have demonstrated exceptional strengths in corporate sustainability. The selection process is highly competitive and based on the S&P Global Corporate Sustainability Assessment, recognized as one of the most comprehensive global ESG benchmarking frameworks.

Industry Leadership in ESG Performance

Laurus Labs' inclusion in the Sustainability Yearbook 2026 highlights the company's significant distinction in the pharmaceutical sector. The yearbook specifically recognizes companies demonstrating strong performance across environmental, social, and governance parameters, positioning Laurus Labs among the world's most sustainable companies.

The recognition underscores the company's systematic approach to sustainability initiatives and its commitment to maintaining high standards in corporate responsibility. This achievement reflects the company's ongoing efforts to integrate sustainable practices across its operations while maintaining competitive performance in the pharmaceutical industry.

Corporate Governance and Compliance

The announcement was made through a formal communication to both BSE Limited and National Stock Exchange of India Ltd. under Regulation 30, demonstrating the company's commitment to transparent corporate governance and regulatory compliance. The disclosure ensures that all stakeholders are informed about this significant recognition in the company's sustainability journey.

Mirae Asset Investment Managers (India) Private Limited has disclosed a substantial acquisition of shares in Laurus Labs Limited, filing the mandatory disclosure under SEBI regulations on February 19, 2026. The acquisition represents a strategic increase in the mutual fund's stake in the pharmaceutical company through open market transactions.

Transaction Details

The mutual fund acquired 111,064 shares of Laurus Labs through open market purchases on February 18, 2026. This acquisition increased Mirae Asset Mutual Fund's total shareholding in the company from 21,626,400 shares to 21,737,464 shares.

Shareholding Structure

The acquisition details reveal the fund's position relative to Laurus Labs' overall capital structure:

Regulatory Compliance

The disclosure was made in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Mirae Asset Investment Managers confirmed that the acquirer does not belong to the promoter or promoter group of Laurus Labs Limited.

The filing was signed by Rimmi Jain, Head of Compliance, Legal and Company Secretary at Mirae Asset Investment Managers (India) Private Limited, and submitted to both the National Stock Exchange of India Ltd. and BSE Ltd., where Laurus Labs shares are listed.

Market Context

Laurus Labs Limited trades on both major Indian stock exchanges with NSE symbol LAURUSLABS and BSE script code 540222. The company's shares carry the ISIN INE947Q01028. The acquisition represents a marginal but notable increase in institutional holding, reflecting continued investor interest in the pharmaceutical sector.

The transaction maintains Mirae Asset Mutual Fund's position as a significant institutional investor in Laurus Labs, with the increased stake demonstrating confidence in the company's prospects within the pharmaceutical industry.